Roles and mechanisms of exosomal non-coding RNAs in human health and diseases

C Li, YQ Ni, H Xu, QY Xiang, Y Zhao, JK Zhan… - Signal transduction and …, 2021 - nature.com
Exosomes play a role as mediators of cell-to-cell communication, thus exhibiting pleiotropic
activities to homeostasis regulation. Exosomal non-coding RNAs (ncRNAs), mainly …

Genomic and phenotypic heterogeneity in prostate cancer

MC Haffner, W Zwart, MP Roudier, LD True… - Nature Reviews …, 2021 - nature.com
From a clinical, morphological and molecular perspective, prostate cancer is a
heterogeneous disease. Primary prostate cancers are often multifocal, having …

[HTML][HTML] Prostate cancer incidence and survival, by stage and race/ethnicity—United States, 2001–2017

DA Siegel - MMWR. Morbidity and mortality weekly report, 2020 - cdc.gov
Prostate Cancer Incidence and Survival, by Stage and Race/Ethnicity — United States, 2001–2017
| MMWR Skip directly to site content Skip directly to page options Skip directly to AZ link …

Genetics and biology of prostate cancer

G Wang, D Zhao, DJ Spring… - Genes & …, 2018 - genesdev.cshlp.org
Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer
remains largely incurable even after intensive multimodal therapy. The lethality of advanced …

Chlorogenic acid for cancer prevention and therapy: Current status on efficacy and mechanisms of action

A Gupta, AG Atanasov, Y Li, N Kumar… - Pharmacological …, 2022 - Elsevier
Chlorogenic acid (CA), also known as 5-O-caffeoylquinic acid, is a dietary phenolic acid
produced by various plant species. CA, is the most ubiquitous compound among the …

Clinical and biological features of neuroendocrine prostate cancer

Y Yamada, H Beltran - Current oncology reports, 2021 - Springer
Abstract Purpose of Review Neuroendocrine prostate cancer (NEPC) is an aggressive
histologic subtype of prostate cancer that most commonly arises in later stages of prostate …

Dominant-negative TGF-β receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication

CC Kloss, J Lee, A Zhang, F Chen, JJ Melenhorst… - Molecular therapy, 2018 - cell.com
Cancer has an impressive ability to evolve multiple processes to evade therapies. While
immunotherapies and vaccines have shown great promise, particularly in certain solid …

[HTML][HTML] European cancer mortality predictions for the year 2022 with focus on ovarian cancer

M Dalmartello, C La Vecchia, P Bertuccio, P Boffetta… - Annals of …, 2022 - Elsevier
Background Cancer mortality rates, though not absolute numbers of deaths, have been
decreasing over the last three decades in Europe. Materials and methods We estimated …

Discovery of ARD-69 as a highly potent proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate cancer

X Han, C Wang, C Qin, W Xiang… - Journal of medicinal …, 2019 - ACS Publications
We report herein the discovery of highly potent PROTAC degraders of androgen receptor
(AR), as exemplified by compound 34 (ARD-69). ARD-69 induces degradation of AR protein …

[HTML][HTML] Potential inhibitory effect of lycopene on prostate cancer

M Mirahmadi, S Azimi-Hashemi, E Saburi… - Biomedicine & …, 2020 - Elsevier
Studying prostate cancer is important due to its high annual incidences and mortality rates in
the world. Although prostate cancer mortality rates are reduced using new therapy …